Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
_256_384.jpg)
The oversubscribed round was led by New York-based HOF Capital and welcomed new investors including Headline, East Ventures, MS&AD Ventures, DG Daiwa Ventures, Pioneer Fund, as well as existing investor Insignia Ventures Partners
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
The hospital will be operated under the name and style of Max Super Speciality Hospital, Dwarka
This is the company’s first partnership arrangement in China
_256_384.jpg)
Extending nonsurgical treatment options for Failing Pulmonic Valve in patients with congenital heart disease using Transcatheter Pulmonary Valve
Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
Subscribe To Our Newsletter & Stay Updated
